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Abstract
Background: Primary Extra-mammary Paget's disease (EMPD) is a very rare cu-
taneous adenocarcinoma affecting anogenital or axillary regions. It is characterized 
by a prolonged course with recurrences and eventually distant metastatic spread for 
which no specific therapy is known.
Methods: Eighteen EMPD (13 vulvar and five scrotal) and ten mammary Paget's 
disease (MPD) cases were comprehensively profiled for gene mutations, fusions and 
copy number alterations, and for therapy-relevant protein biomarkers).
Results: Mutations in TP53 and PIK3CA were the most frequent in both cohorts: 
7/15 and 5/15 in EMPD; 1/6 and 4/7 in MPD HER2 gene amplification was detected 
in 4/18 EMPD (3 vulvar and 1 scrotal case) in contrast to MPD where it was detected 
in the majority (7/8) of cases. TOP2A gene amplification was seen in 2/12 EMPD 
and 1/6 MPD, respectively. Similarly, no difference in estrogen receptor expression 
was seen between the EMPD (4/15) and MPD (3/10). Androgen receptor was also 
expressed in the majority of both cohorts (12/16 EMPD) and (7/8 MPD).Here ARv7 
splice variant was detected in 1/7 EMPD and 1/4 MPD cases, respectively. PD-L1 
expression on immune cells was exclusively observed in three vulvar EMPD. In con-
trast to MPD, six EMPDs harbored a “high” tumor mutation burden (≥10 mutations/
Mb). All tested cases from both cohorts were MSI stable.
Conclusions: EMPD shares some targetable biomarkers with its mammary counter-
part (steroid receptors, PIK3CA signaling pathways, TOP2A amplification). HER2 
positivity is notably lower in EMPD while biomarkers to immune checkpoint inhibi-
tors (high TMB and PD-L1) were observed in some EMPD. Given that no consist-
ent molecular alteration characterizes EMPD, comprehensive theranostic profiling is 
required to identify individual patients with targetable molecular alterations.
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1 |  INTRODUCTION
Primary extra-mammary Paget's disease (EMPD) is a 
very rare, cutaneous adenocarcinoma of uncertain etiol-
ogy commonly affecting anogenital or axillary regions. 
The Surveillance, Epidemiology and End Results (SEER) 
Registry reported an incidence of ~2200 cases in the 
United States over 40 years.1 In contrast to the more com-
mon mammary Paget's disease, which is the manifestation 
of intra-epidermal dissemination of an underlying inva-
sive or in situ breast carcinoma, or secondary extra-mam-
mary pagetoid spread of adenocarcinomas from various 
internal organs, primary cutaneous EMPD lacks an under-
lying malignancy.2 Primary EMPD is a slowly progressive 
disease and is usually diagnosed while at the in situ (in-
tra-epidermal) stage. Following dermal invasion, it me-
tastasizes to regional lymph nodes and potentially other 
distant sites.3 The postsurgical (local) recurrence rate in 
EMPD is 20%-40% and metastatic EMPD has a poor sur-
vival rate.3
Due to its rarity, standard systemic treatment protocol for 
EMPD is currently not established.3-5
In this study, we compared comprehensive molec-
ular-genetic profiles of a cohort of primary EMPD to 
primary mammary Paget's disease (MPD) to detect com-
mon and distinguishing tumor characteristics, provid-
ing additional supportive evidence for optimal therapy 
approaches.6
2 |  MATERIALS AND METHODS
2.1 | Samples
Cases of primary EMPDs [intra-epidermal and invasive (ad-
vanced or metastatic) stages] were retrospectively analyzed 
from the tumor samples submitted for molecular profiling. 
The histologic diagnosis and accompanying diagnostic immu-
nohistochemical workup performed at the referring pathology 
laboratories were reviewed in all cases by a board-certified 
pathologist. Cases of secondary EMPD (intra-epidermal 
spread from an underlying carcinoma, e.g., colon, rectum, 
anus, prostate) were excluded from the study. A cohort of 
mammary Paget's disease (MPD) of the breast was used for 
comparison.
All test assays were performed at CLIA/CAP/ISO15189/
NYSDOH certified clinical laboratory. Additional molecu-
lar assays were performed on de-identified remnant spec-
imens as required. The study was deemed exempt from 
IRB approval and consent requirements were waived in 
compliance with 45 CFR 46.101(b), as all remnant tis-
sues and biomarker data were analyzed with no associated 
identifiers.
2.2 | Immunohistochemistry (IHC)
PD-L1 expression was evaluated in the tumor (TC) and im-
mune cells (IC) using SP142 antibody (Ventana). Any PD-L1 
expression was considered positive if either TC or IC exhibited 
staining. AR (clone 441, Leica Biosystems, Buffalo Grove, IL), 
ER (SP1 clone, Ventana, Tucson, AZ) and PR (1E2, Ventana, 
Tucson, AZ) were analyzed using a ≥10% threshold for nu-
clear positivity. HER2 (4B5 clone, Ventana) was considered 
positive if >10% cancer cells showed complete, circumferen-
tial (3+) expression or exhibited HER2 gene amplification (see 
below). Nine cases (five vulvar and four scrotal) of EMPD and 
four MPD were explored for the expression of the splice vari-
ant of AR (ARv7) using immunohistochemistry (EPR15656, 
Abcam). Three EMPD cases were tested for mismatch repair 
proteins: MLH1 (Clone M1, Ventana), MSH2 (Clone G219-
1129, Ventana), MSH6 (Clone 44, Cell Marque) and PMS2 
(Clone EPR3947, Cell Marque). Topoisomerase 2α (Clone 
3F6, Leica) expression was considered positive if cancer cells 
exhibited nuclear positivity in ≥10%.7
2.3 | Chromogenic in situ hybridization 
(CISH)
Chromogenic in situ hybridization (CISH) was used for 
evaluation of the HER2 (HER2/CEP17 [chromosome 17 
centromere] probe) and TOPO2A (TOP2/CEP17 probe) 
(Abbott Molecular/Vysis, Abbott Park, IL). HER2/
CEP17 and TOPO2A/CEP17 ratios ≥2.0 were considered 
amplified.7
2.4 | Next-generation sequencing (NGS)
All specimens were profiled using massively parallel se-
quencing (NGS). The NGS assay encompasses a 592-
gene panel that utilizes SureSelect XT biotinylated RNA 
probes to capture DNA fragments from exons of 592 genes 
(Agilent).8
We also assessed copy number alterations of 442 genes 
(CNA) with the NGS panel. CNAs were calculated by com-
paring the depth of sequencing of genomic loci to a diploid 
control as well as the known performance of these genomic 
loci over several hundred historical cases. Gains ≥6 copies 
were considered amplified.8,9
Genome-wide mutational signatures were derived by 
analyzing the NGS data as previously reported. After ex-
cluding variants included in dbSNP 137 (National Center 
for Biotechnology Information, National Institutes of 
Health) and 1000 genomes (IGSR, International Genome 
Sample Resource, EMBL-EBI) as presumed germline vari-
ants from a VCF, the number of missense mutations in the 
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VCF is counted and divided by 1.4 Mb, which is the total 
size of target CDSs, to calculate tumor mutational burden 
(TMB). In order to allow comparison of mutational burden 
across tumor types, we converted TMB value to percentile, 
a nonparametric rank that removes the impact of deviations 
from normality in the underlying TMB distribution. The 
percentile is calculated using 500 patient cases that repre-
sent the range of TMB values for that cancer type. When 
there are fewer than 500 cases for a given tumor type, we 
consolidate multiple classifications. Figure 1 shows several 
representative curves for percentile vs. TMB for two differ-
ent combined cancer classifications (“All Carcinoma” and 
“Skin Carcinomas”), contrasting to melanoma and gyneco-
logical cancers (ovarian epithelial and uterine). In Figure 
1, we also include a line at the point where our EMPD pa-
tients TMB values would fall.
Microsatellite instability (MSI) was calculated by direct 
analysis of short tandem repeats in the target regions of se-
quenced genes. The count only included alterations that resulted 
in increases or decreases in the number of repeats. MSI-H was 
defined as ≥46 altered microsatellite loci. The threshold was 
established by comparing NGS with the PCR-based microsat-
ellite fragments analysis results from ~2100 cases.8-10
ArcherDx FusionPlex Assay (ArcherDX) was used for 
detection of gene fusions including ARv7 variant transcript. 
In total, 54 gene targets were analyzed in seven EMPD (five 
vulvar and two scrotal) and four MPD cases.8
3 |  RESULTS
3.1 | Clinicopathologic characteristics of the 
cohorts
The study included 18 cases of primary EMPD and 10 cases 
of MPD (Table 1). Among the EMPD cases, there were 13 
patients with vulvar involvement and 5 cases from scrotum/
perianal region. Most cases represented invasive and/or 
advanced/metastatic EMPD (10/13 vulvar and 5/5 scrotal 
EMPD) (Table 1). All patients were clinically investigated; 
no underlying malignancy was found, thereby ruling out the 
possibility of secondary EMPD. All MPD were localized to 
the breast, half (5) of them had underlying ductal carcinoma 
in situ (DCIS) or invasive mammary carcinoma (Table 1).
3.2 | Steroid receptors profile
Two out of eleven evaluated cases of vulvar EMPD were 
positive for ER. In contrast, AR was positive in the majority 
F I G U R E  1  Plot of tumor mutational burden (TMB) (x-axis) vs percentile (y-axis) for cancer subtypes. Gray vertical lines reflect the TMB 
values of EMPD cases on x-axis and where they intersect with curves for different cancer types is where they fall in terms of percentile (y) for 
the specific groups. Red dots represent all carcinomas; dark green dots—melanomas; blue dots—skin carcinomas, green dots—ovarian surface 
epithelial carcinomas and purple dots—uterine neoplasms
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of the cases (9/11). Among the EMPD of scrotum, ER was 
positive above the 10% threshold in 2/4 cases, while AR was 
positive in 3/5. Similarly, ER expression was observed in 
3/10 MPD while AR was positive in the majority of the cases 
(7/8) (Table 2).
The ARv7 variant transcript was detected by RNA-
sequencing in 1/5 of vulvar EMPD and 1/4 MPD. This obser-
vation was further confirmed by a positive (nuclear) staining 
of ARv7 by IHC in a case of EMPD (Figure 2). No scrotal 
cases expressed the ARv7 variant (0/2).
3.3 | HER2 and TOP2A status
ERBB2/HER2 gene amplification by CISH or CNA/NGS 
was detected in 3/13 vulvar and 1/5 scrotal cases (Figure 3); 
among these all four amplified cases also showed positive 
IHC HER2 expression (Table 1). In addition, one case of 
vulvar EMPD showed positive protein expression by IHC 
without gene amplification. None of the cases harbored 
pathogenic ERBB2 (HER2) gene mutations; however, the 
single HER2 positive scrotal case did harbor a variant of 
unknown significance in the ERBB2 gene (E580K and 
E619K). In comparison, a notably higher HER2 overex-
pression was observed in the small cohort of MPD (7/8).
TOP2A gene amplification was observed in two vulvar 
EMPD (one case had also co-amplification of HER2, Figure 
3) and 1/6 MPD; All amplified cases exhibited Topo2α pro-
tein overexpression by IHC. Additionally, a total of nine 
vulvar and three scrotal cases showed Topo2α protein over-
expression by IHC (Table 2). Two nonamplified MPD were 
also positive for Topo2α by IHC.
3.4 | I-O relevant biomarkers
None of the EMPD cases exhibited aberrant expression of 
PD-L1 in cancer cells (TC, 0/14). Immune cell (IC) ex-
pression of PD-L1 was observed in three vulvar EMPD of 
which two cases had an intense PD-L1 staining of immune 
cells, especially at the tumor-stromal interface (Figure 3).
TMB in vulvar cases varied between 3 and 12 muta-
tions/Mb; three cases had 10 or more mutations/Mb. TMB 
was available for four scrotal cases, 3 of which had 11 mu-
tations/Mb, while the fourth case showed 4 mutations/Mb. 
We placed markers on Figure 1 to allow a comparison of the 
TMB percentiles for each of the listed cancer cohorts against 
the TMB values for EMPD patients.
All tested EMPD, either vulvar (n = 7) or scrotal (n = 4), 
were microsatellite stable. Three cases were additionally 
tested by immunohistochemistry for mismatch repair proteins 
and all cases retained normal expression.
All predictive I-O biomarkers in MPD were negative: 
PD-L1 expression in TC (0/10), high TMB (0/1) and MSI 
status (5/5 stable).
3.5 | Genomic alterations
Pathogenic mutations in TP53 and PIK3CA were the 
most common genomic alterations detected in vulvar 
EMPD (4/10 and 3/10, respectively). PIK3CA mutations 
were found at well-described oncogenic loci (https ://
cancer.sanger.ac.uk/cosmi c/). One case also harbored a 
PIK3CA gene amplification by NGS, suggesting amplifi-
cation as an alternate mechanism of pathway activation. 
Pathogenic SETD2 gene mutations were present in two 
cases (20%) while other gene mutations (BRCA1, RB1, 
BCOR, and MUTYH) were rare and affected only one 
case each. Interestingly, one case harbored two separate 
nonsense mutations in SETD2, suggesting complete gene 
activation. In scrotal EMPD, TP53 and PIK3CA muta-
tions were present in n = 3 and 2 of 5 cases, respectively. 
In one scrotal EMPD, a pathogenic MUTYH gene muta-
tion (G393D) was found representing a germline variant 
(MUTYH-associated polyposis is an autosomal recessive 
polyposis syndrome caused by bi-allelic pathogenic ger-
mline variants in the MUTYH gene.11 No other CNV or 
gene fusions were detected in any of the tested cases.
PIK3CA mutations were also common in MPD (4/7) 
while TP53 mutations were observed in 1/6 tested cases. 
Notably, three out of four PIK3CA mutated cases were 
ER+. Although rare, several genomic alterations were ex-
clusively detected in MPD: CHEK2 and CDK12 gene mu-
tations (1 case each) and MLLT6 (2/5) and MDM2 gene 
amplifications (1/5) (Table 3).
Tumor type (number)
Extra-mammary Paget's disease 
(n = 18)
Mammary Paget's disease 
(n = 10)
Age: Mean and range 61 y (49-82 y) (vulva)
73.5 y (69-79 y) (scrotum)
62 y (37-76 y, all females)
Sample site Vulva (n = 13) (10/13 advanced or 
metastatic)
Scrotum (n = 5) (all metastatic)
All primary (n = 10)
5 with underlying DCIS 
or invasive mammary 
carcinoma
T A B L E  1  Patients’ demographics and 
sample sites from the two cohorts
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4 |  DISCUSSION
In contrast to mammary Paget's disease, primary EMPD is 
a rare and slowly progressive skin adenocarcinoma. In its 
superficial phase and if surgically resectable, it is associ-
ated with a good prognosis.12 Once it invades dermis and 
deep structures, the risk of lymph node and distant metas-
tases significantly increases.13,14 Due to its rarity, no sys-
temic, comprehensive evaluation of targeted therapies has 
been performed. Selected cases of EMPD (with amplified 
ERBB2/HER2 gene) have been successfully treated with 
trastuzumab alone or in combinations with chemother-
apy.4,15-21 In contrast to MPD, we found overexpression 
and HER2 gene amplification in a minority of cases, and 
a co-amplification with TOPO2 in a single case of vulvar 
disease. Amplification of TOPO2 gene and expression of 
Topo2 protein in several cases of EMPD is a novel find-
ing in our cohort. TOPO2α is the target for anthracyclins22 
chemotherapy and this biomarker was frequently altered in 
our study. Topo2α protein is commonly expressed across 
human cancers while TOP2A gene amplification is rare, 
with only few cancer types (gallbladder and gastroesopha-
geal/esophageal carcinomas) exhibiting TOP2A amplifica-
tion in >10% of the cases.23 Based on the Topo2α/TOP2A 
status alone, a substantial proportion of the patients with ad-
vanced/metastatic EMPD may benefit from anthracycline-
based chemotherapy.
Although early studies reported the lack of ER expression 
in EMPD,24-26 we detected ER positivity in a small number of 
EMPD. Garganese et al recently reported ER positivity in 70% 
of vulvar EMPD.27 Importantly, this may represent a potential 
therapeutic target as Iijima et al reported a successful treatment 
of ER + scrotal EMPD with tamoxifen.28 In addition, Wachter 
et al recently reported ER expression in 27% of MPD.29
Similar to MPD from our cohort, androgen receptor 
(AR) over-expression is commonly seen in EMPD (54%-
90%).24,27,30 AR protein expression has also been shown 
to correlate with the invasiveness in EMPD.3 A successful 
treatment with combined androgen blockade (bicalutamide/
targeted anti-AR/) and leuprolide acetate (LH-RH analogue) 
has been published in a single case report.31 Our study fur-
ther confirms earlier observations of frequent AR expres-
sion.24,32 We also report for the first time, the presence of 
the ARv7 transcript, a pathogenic splice variant of AR in 
single cases of EMPD and MPD. This variant of AR lacks 
the ligand-binding domain (a target of anti-AR drugs such 
as enzalutamide and abiraterone), but retains its constitutive 
activity.33 Consequently, ARv7 causes resistance to anti-AR 
F I G U R E  2  Hematoxylin and Eosin (H&E) slide of the metastatic (lymph node) case of EMPD (left image) with diffuse and strong positivity 
for ARv7 by immunohistochemistry (right image). The figure in the lower right corner depicts the structure of the Androgen receptor (AR) gene and 
its associated ligand-independent variant ARv7. ARv7 can be reliably detected by immunohistochemistry (IHC) as shown in the upper right image. 
Transcriptome structure for AR gene and its splice variants modified from Luo J. Asian J Androl 2016;18: 580–585
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drugs as confirmed in patients with prostate cancer.33 Given 
the common AR expression and the lack of ARv7 in the ma-
jority of AR + EMPD, these patients may be amenable for 
the trials with anti-AR drugs.31,34
Immunotherapy with immune checkpoint inhibitors has 
become the cornerstone of treatment for several advanced 
cancers such as NSCLC, melanoma, urothelial carcinoma, 
head and neck carcinomas, and triple negative breast car-
cinomas. For some of these cancers, approval is based on 
companion diagnostic testing for the expression of PD-L1 
in either cancer cells (TC), immune cells (IC; mononuclear 
cells, excluding polymorphonuclear leukocytes), or both 
(eg combined positive score), depending on cancer types. 
In our study, none of the cases exhibited aberrant PD-L1 
expression on neoplastic cells (TC 0) and three EMPD 
cases had intense PD-L1 positive immune cells infiltrate. 
Recently, Mauzo et al demonstrated low (3/21) PD-L1 
expression on cancer cells while immune cells (IC) ex-
pressed PD-L1 in 15/21 of the EMPDs. In addition, PD-L1 
expression in ICs was significantly lower in patients with 
HER2-positive compared with HER2-negative EMPD 
cancers.35 Duverger et al reported positive expression of 
PD-L1 on cancer cells in n = 4/7 invasive EMPD,36 while 
Karpathiou et al reported that EMPD are characterized 
by the intense lymphocytic response but without PD-L1 
expression on either cancer or immune cells.37 A single 
patient in our cohort was included in a basket trial with 
Pembrolizumab without clinical benefit and a later tumor 
sample analysis revealed no PD-L1 positivity, but HER2 
amplification was detected and Herceptin therapy was ini-
tiated (data not shown). Interestingly, one of the TOP2A-
amplified cases also exhibited PD-L1 positivity in IC 
giving a potential for combination chemotherapy with im-
mune checkpoint inhibitors.6
Additional immune-oncology markers such as high TMB 
are under investigation as part of late phase clinical trials.38,39 
However, it remains to be seen whether immune checkpoint 
inhibitors will have efficacy for the treatment of EMPD. We 
observed some patients with high TMB and the presence of 
PD-L1 in IC (TIL) in our study of EMPD, indicating that these 
F I G U R E  3  The same case provided in Figure 2 with a PD-L1 positivity in the inflammatory (immune cells, IC; upper right image, white 
arrow); Please note the absence of PD-L1 expression in tumor cells (TC; white arrow); Lower two images show HER2 (left) and TOP2A gene 
co-amplifications (right image) (Chromogenic in situ hybridization). The black spots on the images reflect HER2 and TOP2A gene copy numbers, 
respectively, while the red spots indicate the CEP17 region
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patients may also benefit from treatment with immune check-
point inhibitors (ClinicalTrials.gov Identifier: NCT02834013). 
We suggest there is value in using a relative ranking for TMB. 
One simple method is converting TMB to rank (percentile) 
using a cohort of patients with the same cancer diagnosis. 
TMB percentile may be a more meaningful way to assess the 
likely impact global mutations have on therapy options.
MSI is an additional measure of genome instability, 
leading to possible therapies. Notably, all EMPD cases 
from our cohort were MSI stable (by NGS and IHC), 
which is in stark contrast to the study of Kang et al that 
showed that 8/20 EMPD harbored germline mutations of 
mismatch repair genes (MMR), five of which were MSI-
H.40 However, both studies have rather limited number of 
cases studied, and vigilance about MSI status in EMPD is 
warranted. In contrast to EMPD, MPD cases were entirely 
devoid of PD-L1 expression; all cases were also MSI stable 
and lacked high TMB, making MPD patients unlikely to 
respond to immune checkpoint inhibitors. These results are 
in line with previous data.37
Next-generation sequencing from this cohort is in line with 
previous studies.41-43 In contrast to Kiniwa et al who reported 
mutations in ERBB2 gene,43 we found only ERBB2 amplifica-
tion but no pathogenic ERBB2 mutations in any of our cases. 
The presence of mutations within the PIK3CA/AKT pathway 
indicates a potential for targeted therapeutic trials with newer 
generation of PIK3CA inhibitors, either alone or in combina-
tion with other therapies.44,45 Recently, a PIK3CA inhibitor 
was FDA approved for the treatment of ER-positive/HER2-
negative breast cancers harboring known pathogenic PIK3CA 
mutations in combination with anti-ER therapy (fulvestrant) 
(FDA site, accessed October 12, 2019). One of the scrotal 
EMPD from our cohort with PIK3CA mutation was ER-
positive. Notably, three out of four PIK3CA-mutated MPD 
cases were ER-positive and are potential candidates for the 
treatment with PIK3CA inhibitors. Similarly, AR+/PIK3CA 
mutated cases might benefit from the combined treatment 
with anti-AR and PIK3CA inhibitors as recently shown in 
phase IB/II clinical trial with triple-negative breast cancer.45
We report here for the first time two EMPD cases with 
SETD2 gene mutations, which have not been previously 
described in this cancer. Inactivating SETD2 mutations are 
common in clear cell renal cell carcinomas, but have been 
described at low frequencies across additional tumor types. 
SETD2 is responsible for trimethylation of lysine 36 of 
Histone H3 (H3K36),46 which is involved in various cellular 
processes. SETD2-mutant cancers have showed a substantial 
decrease in global H3K36me3 levels.47 Additionally, the loss 
Biomarker
Extra-mammary Paget's 
disease (positive/total)
Mammary Paget's 
disease (positive/total)
Steroid receptors
Estrogen receptor (ER) 4/15 3/10
Androgen receptor (AR) 12/16 7/8
ARv7 1/7 1/4
Genomic alterations
HER2 (ERBB2) (amp.) 4/18 7/8
TOP2A (amp.) 2/12 1/6
PIK3CA 5/15 4/7
TP53 7/15 1/6
SETD2 2/15 0/5
BRCA1 1/15 0/5
RB1 1/15 0/7
MLLT6 0/15 2/5
CHEK2 0/15 1/5
CDK12 0/15 1/5
MDM2 (amp.) 0/12 1/5
I-O biomarkers
PD-L1 expression 3/14 (vulva, IC+) 0/10
High tumor mutational burden* 6/11 0/1
Microsatellite instability (MSI) Stable (n = 11) Stable (n = 5)
Abbreviations: Amp., Amplification by In situ hybridization; IC, Inflammatory (immune) cells; I-O, 
Immuno-oncology.
*Threshold for TMB-high was set at ≥ 10 
T A B L E  3  Comparative overview 
of the molecular features of the extra-
mammary- and mammary Paget's disease
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of function of SETD2 has been shown to sensitize tumors to 
PI3KB inhibitors48 and is under investigation as a target for 
other agents in phase I and II clinical trials, making it a novel 
potential therapeutic target in this disease.
We conclude that EMPD shares some targetable biomark-
ers with its mammary counterpart (steroid receptors, PIK3CA 
pathways, TOP2A amplification). HER2 positivity is notably 
lower in EMPD while expression of biomarkers to immune 
checkpoints (high TMB and IC PD-L1) was observed in 
some EMPD. In selected EMPD cases with more than one 
targetable biomarker, a combination therapy may be a part of 
the precision medicine approach. Therefore, comprehensive 
case-by-case analysis is required to maximize benefits of the 
targeted therapeutic for patients with this rare disease.
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